Calling all college health professionals! Stop by our table at the Southern College Health Association Regional Meeting to learn more about how same-visit CT/NG results are re-shaping how university students access STI care. #SCHA #binxio
binx health
医疗设备制造业
Boston，Massachusetts 11,825 位关注者
Creating new categories of healthcare solutions that put on-demand testing where people need it most.
关于我们
binx health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer. binx is developing a suite of offerings that service healthcare needs where people live, work and shop.
The Company’s io? platform is designed to offer rapid PCR-based results, up to 24-plex, from sample-in-to-answer in about 30 minutes, greatly accelerating today’s multiple day standard-of-care central lab testing paradigm. binx is driving solutions to take place in retail clinics, supermarkets, primary care offices, and at home. It does it through a suite of mobile and digital offerings.
binx health investors includes financial investors, Johnson & Johnson Innovation, Novartis Venture Fund, LSP Venture Capital, BB Biotech, RMI Investments and Technology Venture Partners and strategic investors, Consort Medical (whose wholly owned subsidiary Bespak are the makers of the company’s low-cost, proprietary multi-plex cartridges) and China-based Wondfo Biotech.
binx health is a global company and has locations in Boston, MA and Bath UK.
For further information visit www.mybinxhealth.com.
- 网站
-
https://mybinxhealth.com
binx health的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 51-200 人
- 总部
- Boston，Massachusetts
- 类型
- 私人持股
- 创立
- 2005
- 领域
- Point-of-care in vitro diagnostic test development、Electrochemical detection、Micro-fluidic device development、Instrumentation development、consumer digital、digital health和at-home testing
地点
binx health员工
-
Mike Karsonovich
-
Stan Lapidus
Board member
-
Jack Crowley, CPA, MBA
Chief Financial Officer | Public and Private Equity-backed Companies
-
ATUL SINGH
PhD, PMP? | Project Management Professional | Molecular Diagnostics & Assay Development |CRISPR Application | Synthetic Biology | Microbial genetics…
动态
-
What are you doing on March 3rd? If you don't?have plans, come visit the binx health team at?#UCConnect2025?in Louisville to learn more about how the binx io is helping Urgent?Care clinics grow their business and improve the quality?of care they deliver.?#OnPaceForProgress #binxio
-
-
Join us in celebrating this month's #EmployeeSpotlight ?? with our Senior AR Accountant, Nicole Freeman! #OneTeam
-
Did you know that point-of-care testing plays a critical role in reducing improper treatments, overprescribing, and tackling the growing challenge of antibiotic resistance with chlamydia and gonorrhea treatment? In our latest press release, we dive into why empowering clinicians with timely, accurate diagnostics is the key to smarter, more effective STI treatment decisions and patient care. #binxio
-
Join us in celebrating this month's #EmployeeSpotlight ?? with Product Development Director, Dr Laura R. Kemp!
-
Join us in celebrating this month's #EmployeeSpotlight ?? with Alyssa Luber! Alyssa values opportunities to interact and work with a variety of unique & inspiring people across all sectors of healthcare everyday!
-
binx health applauds Planned Parenthood Keystone for promoting access to healthcare services for Central and Eastern Pennsylvania since 1926.?The team not only supports reproductive health,?education, wellness exams, cancer screenings, but offers STI testing and treatment.?We are proud to support this dedicated team and are humbled by their embrace of the binx CT/NG test for rapid patient-centric results.?#PPK #binxio
-
-
binx CEO,?Jeff?Luber, shares the company’s rise from research entity to national force in molecular point-of-care testing in sexual health. From FDA clearance, through CLIA-waiver, blue-chip investor backing, global manufacturing, and the inking of five national marquee partnerships, the company is enjoying its commercial climb as the only player of its kind in the $2B category for male and female testing. Its small but mighty internal team of binxers ?? have ignited the paradigm shift to rapid test and treat! Great turnout and another great event hosted by LSI Europe. #LSIEurope24
-
-
???? ???????? ???????? ?????????????????????? ???? ???????????? ???? ????????? ?????? ???????????????????? ?????????????????? ?????? ?????????? ?????? ?????????????? ?????????????? ?????????????? ?????????? ?? ???????? ?????????????????????? ???? ????????????. ?????? ?????????? ???????????????????? ???????? ???? ?????? “??????-?????????? ??????” ???? ??????????.?? “??????-?????????? ??????” ???? ???????????? ?????????? ?????????? ???? ?????? ?????????????? ????????’?? ???????? ?????? ?????? ???????????? ???????????????????? ???? ????????????, ?????????? ?????? ???? ?????????????????? ???????? ?????? ???????? ?????????????? ???? ???????????? ???? ??????-?????????????? ???? ???????????????? ???????? ????????????.? ???????????????????????? ?????????? ?????????? ?? ???????? ???????????? ???? ?? ?????? ?????????? ???????? ???????? ?????????????????? ???? ?????? ???????????????? ??????, ??????????????????????, ??????????????????????, ???? ?????????? ???????????????? ???? ?????? ????????????????????????’?? ????????????????????????.? ?????? ???????????????? ?????? ???? ?? ???????? ???????????? ???? ???????????????????? “??????-?????????? ??????” ?????????????? ???? ???? ?????? ?????????????????? ???? ?????? ????????????????????????’?? ???????????????? ???????? ?????? ???? ???? ?????? ???????? ???? ?????? ??????-?????????????? ???? ???????????????? ????????????????????????. ???? ?????????????? ?????????? ???? ?? ?????????????? ????????—???????? ?????? ???????? ?????????????? ????????-??????????????????, ?????????????????? ?????????????????? ???? ?????????? ???????????????????? ?????? ???????????????? ????????????????????????. “??????-?????????? ??????”, ???? ???????????????? ?????? ???? ?? ???????? ????????????, ???????????????? ?????? ???????? ???? ?????? ????????-???????????????????? ?????????????? ???????????????? ?????????? ???????? ??????????????????????, ?????????????????? ?????????? ?????????? ?????? ???????????????? ???????? ???????????? ???? ???????? ?????? ???????????????????? ???????? ???????????????????????? ?????? ????????-???????????????????? ??????????????. ?????????? ?????????????? ?????????????????????? ?????????????? (????), ???????????????????????? ?????????????????????? ??????????????????????????????, ?????????????? ?????????????? (????), ?????????????? ????????????????????, ?????? ?????????????????? ????????????????????????????. ???????????????????????? ???????? ?? ???????? ?????????????????????? ???? ???????????? ?????????? ???????????????? ???????? ?????????????? ???????? ???? ?????????????? ???? ?? ???????? ?????????????????????? ???? ???????????????????? ???? ?? ???????? ?????????????????????? ???? ?????????????????????????? ???? ???????? ???????????????? ???? ?????? ???????????????? ???????? ??????????????.?? ??. ??????????://??????.??????.??????/????????????????????/????????????/????????????-??????????/????????????????????????_????????_??????????.???????
-
-
binx health CEO, Jeffrey R. Luber shares vision and value of rapid STI testing! Join him at #LSIEurope24 next week to learn more about binx health!
binx health? (#LSIEurope24 Innovator) supplies CLIA-waived point-of-care (POC) infectious disease PCR tests which use electrochemical hybridization probes to indicate the presence of organisms such as Chlamydia trachomatis and Neisseria gonorrhoeae. Unlike optical PCR systems, the binx? io instrument requires no recalibration or maintenance when it is relocated between locations, enabling users to deliver care in an on-demand basis. Over the past 5 years (2018-2022), the total reported STIs in the USA has increased 1.9%, where over half of reported cases (13 million) were among young people 15-24 years of age. Treatment of STIs depends on testing, but where symptoms are not detected in 50% of males and 70% of females, current testing and screening approaches are ineffective to curb the infections. The majority of CT/NG testing involves sending samples to central laboratories, where results may not be delivered for 3-14 days. Patients can be lost to follow-up and left untreated. The binx? CT/NG assay provides test results for male and female patients in around 30 minutes, allowing clinicians to treat patients at the time of visit. Using a robust and portable binx io instrument, healthcare teams can bring molecular testing capacity to communities where STI testing is limited or absent. Binx Health has recently raised an additional $65 million in April 2024 to drive the growth of point-of-care testing and is driving the adoption of POC testing through five major medical product distributors in the USA. Binx Health believes that routine testing and improved access to CT/NG testing will have a marked impact on curbing the spread of STIs We’re excited to announce that CEO Jeffrey R. Luber, has been selected to present Binx Health at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Jeff and learn more about Binx Health.
-